Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Michele Brignole,
A survey conducted by the Associazione Italiana di Aritmologia e Cardiostimolazione in 343 implanting centers in Italy, defibrillation testing (DT) is not performed in 30% of patients, most often in the absence of legitimate reasons. Certain physicians are concerned about the risk of complications related to the induction test. However to be consistent with the rules of good clinical practice, effective defibrillation testing (DT) is mandatory. The clinical impact of DT versus no DT remains unclear – its non-negligible complication rate needs to be weighed against its long-term potential benefit.
The standardised requirements for cardioverter defibrillator (ICD) implantation, with or without cardiac resynchronisation therapy (CRT), include defibrillation testing (DT), which consists in the induction and termination of ventricular fibrillation (VF).
This procedure has been set from the early days of ICD therapy in order to test the reliability of the device and to measure the defibrillation threshold. Carrying out an effective DT is considered mandatory to be consistent with the rules of good clinical practice.
However, since the implantation procedure of ICD has been markedly simplified and surgical risk today is very low, defibrillation testing can be considered as the most critical part of the implantation procedure itself.
Although the risk associated with DT is usually low, serious complications may occur as a consequence of this practice. These complications include
This knowledge comes from small single-center retrospective surveys (1) and from anecdotal experiences. However, in the absence of data of large populations from multicentre registries, the real magnitude of intra-operative complications related to DT is still largely unknown.
Despite the fact that the standardised approach still requires a VF induction test, data coming from real world experience suggest that an increasing number of first implantation procedures are performed without any induction test at all. It seems that physicians may be concerned about practicing DT in selected patients considered at very high clinical risk. For example, in two single-centre populations, Russo et al (2) reported a lack in induction testing in 4.7% and Pires et al (3) in 24% of their patients respectively. Reasons for this lack in induction testing included
The AIAC (Associazione Italiana di Aritmologia e Cardiostimolazione) has recently conducted a systematic nation-wide retrospective survey in order to determine how often and for what reasons intra-operative DT was or was not performed, and the complication rate related to induction testing (4). An ad-hoc questionnaire was sent to all 343 centres implanting ICDs listed in the database of Italian ICD Registry of AIAC which virtually represent the totality of Italian implanting centres. The survey was limited to patients undergoing initial ICD implantation during the year 2005.
Among a total of 8820 first ICD/CRTs implanted in Italy during the year 2005, the data of 7857 (89%) implantations (38% of whom CRT) performed in the 229 centres which participated to the survey were analysed. Of these,
At multivariable analysis, performed in a subset of 1206 patients from 107 centres,
This nation-wide survey is the largest ever performed and covers 89% of the overall Italian first implantations during the year 2005.
The main result is that, in the real world clinical practice, DT is not performed in 30% of patients, most of these in absence of legitimate reasons, despite the fact that DT is still considered part of the standard procedure of ICD implantation.
There is a wide heterogeneity between centres and more than a quarter of Italian centres do not perform DT in 50% of their patients. These figures are much higher than those expected from the literature (2, 10) and reflect a spontaneous non-conformist opinion of several physicians that overlooks the current recommendations of ICD companies. Given the high numbers involved, this behaviour deserves explanation and actions.
In litterature there are few reports from small studies concerning intra-operative complications.
Moreover, anaesthesia has a cardiac depressive effect in adjunction of VF induction (6). Patient at implantation could have worse clinical conditions that could improve later with CRT, thus decreasing the risk of complications related to DT; for example a DT delayed up to 2 months after CRT device implant, when patient’s clinical condition improved due to CRT, showed effectiveness without compromising safety (7).
On the other hand, few data are available regarding the risk of death due to failure of the ICD to interrupt a VF during long-term follow-up. Sudden death in patients with ICD is reported to range approximately from 1.8% to 2.6% during the 1 to 3 years of follow-up (3, 8, 9). Of these, an analysis of the mechanisms of sudden death, with data retrieved from ICD diagnostic memory, showed that only a quarter of the cases could be attributed to shock failure during VF (8). Therefore, we can assume that the sudden death rate potentially attributable to shock failure ranged form 0.45% to 0.65% during the 1 to 3 years of follow up. This percentage is very similar to the percentage to the intra-operative deaths observed following VF induction during implantation.
In addition, there are no data that specifically demonstrates increased mortality among patients with high DT thresholds at implant and in a recent study (3) success of ICD therapies and sudden-death-free survival were similar in patients who had defibrillation threshold measurement, safety margin testing or no testing.
Is it time to change current standard of performing DT at the time of ICD implantation? The question has been previously raised by authoritative authors (2,3,10,11,12).
There is no evidence-based answer yet. Reasons in favour and contrary to DT are summarised in Table 2. The clinical impact of DT versus no DT will remain unclear until the not negligible introperative complication rate is weighed against the long-term potential benefit of DT.
Until long-term follow-up data regarding the safety and efficacy of ICD implantation in large groups of patients in whom DT is not performed are available, DT should be considered a standard practice. However, data from literature and from the present study support the need to perform such large multicentre studies and the urgency for scientific sub-speciality societies to give precise recommendations.
In the real world practice, DT is not performed in a substantial number of patients, most of these in absence of legitimate reasons. This finding, much higher than that expected from the literature, reflects a spontaneous non-conformist opinion of several physicians that goes beyond the current recommendations. Given the high numbers involved, this behaviour deserves explanations and actions. The results of available literature form the background for future trials aimed to evaluate the clinical benefit of performing DT and underline the urgency for scientific sub-speciality societies to give precise recommendations.
Centres invited to participate : 343Centres that participated : 229 (67%)Total number of first implant procedures : 7857- with intraoperative defibrillation test : 5501 (70%)- without intraoperative defibrillation test 2356 (30%)Total number of complications related with defibrillation test : 22 (0.4%)Death : 4 (0.07%)Cardiopulmonary arrest requiring resuscitation : 8 (0.15%)Cardiogenic shock : 6 (0.11%)Stroke : 3 (0.05%)Pulmonary embolism : 1 (0.02%)
Reasons in favour of induction
• Standard practice for ICD implant • Most device safety studies required DT at implant • DT allows the choice of corrective measures at implant in case of high threshold • DT ensures that the system provides appropriate sensing of VF • DT may include defribrillation threshold evaluation for better ICD programminReasons in favour of non-induction• No data specifically demonstrates increased mortality among patients with high DT thresholds • Quite small probability of a high threshold and a failed implant with current technology • The nature of defibrillation threshold is probabilistic and repeated shocks below threshold can be effective • The shocks may cause hemodynamic compromise • The cardiac depressive effect of anaesthesia in adjunction of VF induction • In the great majority of patients receiving an ICD, the initial spontaneous life-threatening arrhythmia is VT and not VF, thus a DT at implant imposing an additional risk which most would not have in their lives • Patient at implant could have worse clinical conditions that could improve later with CRT, thus decreasing the risk of complications related to DT • In one retrospective analysys, success of ICD therapies and sudden-death-free survival were similar in patients who had defibrillation threshold testing, safety margin testing, and no testing
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 2005; 28: 926-932.
2. Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, Verdino RJ, Nayak HM, Callans DJ, Patel V, Marchlinski FE. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm. 2005; 2: 456-461.
3. Pires LA, Johnson KM. Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? J Cardiovasc Electrophysiol. 2006; 17: 140-145.
4. Brignole M, Raciti G, Bongiorni MG, De Martino A, Favale S, Gasparini M, Luise R, Occhetta E, Proclemer A: Defibrillation testing at the time of ICD implantation in the clinical practice. A nation-wide survey. Europace 2007; 9: 540–543
5. Tokano T, Bach D, Chang J, Davis J, Souza JJ, Zivin A, Knight BP, Goyal R, Man KC, Morady F, Strickberger SA. Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol 1998; 9: 791-797.
6. Gilbert TB, Gold MR, Shorofsky SR, Hasnain JU, Ferguson MK, Foster AH. Cardiovascular responses to repetitive defibrillation during implantable cardioverter-defibrillator testing. J Cardiothorac Vasc Anesth. 2002; 16: 180-5.
7. Gasparini M, Galimberti P, Regoli F, Ceriotti C, Bonadies M. Delayed defibrillation testing in patients implanted with biventricular ICD (CRT-D): a reliable and safe approach. J Cardiovasc Electrophysiol 2005; 16: 1279-1283.
8. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002; 39: 1323-1328.
9. Fiek M, Zieg B, Matis T, Hahnefeld A, Reithmann C, Steinbeck G. Analysis of the cause of death of ICD patients during long-term follow-up. Herzschrittmacherther Elektrophysiol 2006; 17: 6-12.
10. Favale S. Test di defibrillazione durante l’impianto di defibrillatore automatico: è ancora necessario? G Ital Aritmol Cardiostim 2005; 2: 73-77 (PDF)
11. Strickberger SA, Klein GJ. Is defibrillation testing required for defibrillator implantation? J Am Coll Cardiol. 2004; 44: 88-91
12. Neuzner J. Is DFT testing still mandatory? Herz. 2005 Nov; 30: 601-6.
Dr M. Brignole Lavagna, Italy Fellow of the European Society of Cardiology
© 2017 European Society of Cardiology. All rights reserved